Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022
prnewswire.com
news
2022-10-19 13:00:00

Synaptogenix is one of few companies developing therapeutics for advanced Alzheimer's disease (AD); no such drug has received FDA approval to date
Topline data from NIH-supported Phase 2 clinical trial for advanced AD patients expected in current quarter 
NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Synaptogenix, Inc.Â (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that President and Chief Scientific Officer Daniel L.
